Coeptis Therapeutics Holdings, INC. (COEPW) — 8-K Filings

8-K Filings (15)

• Coeptis Therapeutics Enters Material Definitive Agreement — Apr 28, 2025 Risk: medium
  On April 25, 2025, Coeptis Therapeutics Holdings, Inc. entered into a material definitive agreement. The company, formerly known as Bull Horn Holdings Corp., is
• Coeptis Therapeutics Announces Board and Compensation Changes — Mar 27, 2025 Risk: medium
  On March 21, 2025, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements.
• Coeptis Therapeutics Files 8-K for Equity Sales — Jan 24, 2025 Risk: medium
  On January 17, 2025, Coeptis Therapeutics Holdings, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The co
• Coeptis Therapeutics Files 8-K — Jan 22, 2025 Risk: low
  On January 21, 2025, Coeptis Therapeutics Holdings, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a rout
• Coeptis Therapeutics Files 8-K with Bylaw Amendments — Dec 27, 2024 Risk: low
  On December 26, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing amendments to its articles of incorporation and bylaws. The company also
• Coeptis Therapeutics Stockholders to Vote on Share Increase — Dec 20, 2024 Risk: medium
  On December 18, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing a special meeting of stockholders. The primary purpose of this meeting w
• Coeptis Therapeutics Raises $1.5M Via Convertible Notes — Dec 17, 2024 Risk: medium
  On December 12, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing the closing of a private placement of convertible promissory notes. The
• Coeptis Therapeutics CMO Resigns; Interim Appointed — Dec 4, 2024 Risk: medium
  On December 3, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing the resignation of Dr. Robert L. Johnson as Chief Medical Officer, effect
• Coeptis Therapeutics Enters Material Definitive Agreement — Nov 6, 2024 Risk: medium
  On November 1, 2024, Coeptis Therapeutics Holdings, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibit
• Coeptis Therapeutics Files 8-K: Accountant Change & Financials — Sep 30, 2024 Risk: low
  On September 30, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report. The filing primarily concerns changes in the registrant's certifying accountant
• Coeptis Therapeutics Faces Delisting Notice — Sep 19, 2024 Risk: high
  Coeptis Therapeutics Holdings, Inc. filed an 8-K on September 19, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The compa
• Coeptis Therapeutics Restates Financials Due to Accounting Review — Aug 14, 2024 Risk: medium
  Coeptis Therapeutics Holdings, Inc. announced on August 9, 2024, that it will not rely on previously issued financial statements for the fiscal year ended Decem
• Coeptis Therapeutics Faces Nasdaq Delisting Warning — Jul 31, 2024 Risk: high
  Coeptis Therapeutics Holdings, Inc. received a notification from Nasdaq on July 30, 2024, indicating it is not in compliance with the minimum bid price requirem
• Coeptis Therapeutics Raises $1.5M in Private Placement — Jun 20, 2024 Risk: medium
  Coeptis Therapeutics Holdings, Inc. announced on June 14, 2024, the closing of a private placement of approximately $1.5 million in gross proceeds. The company
• COEPTIS THERAPEUTICS FACES DELISTING THREAT — Feb 1, 2024
  Coeptis Therapeutics Holdings, Inc. (COEP) announced on January 29, 2024, that it received a notice of delisting or failure to satisfy a continued listing rule

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX